Augmentation therapy with α1-antitrypsin patterns of use and adverse events Academic Article uri icon

Overview

MeSH Major

  • Braces
  • Exercise Therapy
  • Intervertebral Disc
  • Low Back Pain
  • Spinal Diseases

abstract

  • We conclude that augmentation therapy was generally well tolerated and, consistent with ATS guidelines, physicians generally did not prescribe augmentation therapy for subjects with FEV(1) > or = 80% predicted. However, the large percentage of subjects with FEV(1) <80% predicted not receiving augmentation therapy and the frequent use of 2- to 3-week or monthly dosing reflects variation of practice from suggested treatment guidelines.

publication date

  • May 2003

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1378/chest.123.5.1425

Additional Document Info

start page

  • 1425

end page

  • 34

volume

  • 123

number

  • 5